MCL5008

MCL5008 is an investigational oral, once-daily therapy being developed by MelliCell for the treatment of obesity. The drug is designed to target adipocyte dysfunction, a core driver of metabolic disease, using a mechanism intended to reverse the "sick" state of fat cells rather than simply suppressing appetite. Identified through MelliCell's proprietary screening platform—which utilizes human patient-derived adipocytes—MCL5008 represents a novel approach to weight management that focuses on restoring healthy fat cell metabolism. While the company's formal pipeline also lists MCL5000 for obesity, MCL5008 is highlighted as a key oral candidate in their development portfolio.